RiboForge is a biotech startup developing small molecule therapeutics targeting RNA structures.
Market:
The market for RNA-targeted small molecule drugs is substantial. Multiple indications in oncology, neurodegenerative disorders, and genetic disease involve a validated RNA target with potential for small molecule antagonist discovery. Small molecule therapies have key advantages over competing technologies (such as antisense or gene therapy) in delivery, toxicity, dosing, and cost of manufacture.
Technology:
We are pioneering a structure-based approach to RNA-ligand discovery with the aim of delivering small molecule binders with enhanced specificity and drug-like properties.
Advantages:
- Structure-guided development
- Potentially superior specificity and drug-likeness
- Exploring unique chemical space
Development Stage:
- Prototype
Patents Issued:
- Coming soon!
Select Publications:
- Coming soon!
Contact:
Portfolio Companies
- Anaco
- CDR3 Therapeutics, Inc.
- Dalton Bioanalytics
- Diatom Biolab
- Eximius Diagnostics
- Giant BioSystems
- Hikari Medical Technologies
- ImmunoVec
- MedStat AI Inc.
- Mervyn's Petcare, Inc.
- Meteor Biotech, LLC
- My Block Skin, Inc.
- Nanomega CryoAI
- NEXT-TFX, Inc.
- Paralos Bioscience Inc.
- Pelage Pharmaceuticals
- Pluto Immunotherapeutics
- Prosper DNA
- Protean Research, Inc.
- Purpose Bio
- RaizDx
- RiboForge
- Saku Biosciences, Inc.
- SolGrapH, Inc.
- Sorriso Pharmaceuticals
- Thermeutics, Inc.
- Vault Pharma
- Veergen, Inc.
- Yuyu Bio, Inc.